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Summary
While practised for over thousand years, there is
presently a renaissance in the interest of using of
faecal transplantations to modify the intestinal micro-
biota of patients. This clinical practice consists of
delivering large amounts of bowel microbes in
various forms into the intestinal tract of the recipient
that usually has been cleared previously. The major
reason for the popularity of faecal transplantations is
their effectiveness in treating a variety of diseases.
Hence, there is a need to develop this procedure to
the next level. While there are various developments
to select, standardize and store the donor microbiota,
it is more challenging to understand the intestinal
microbial communities and develop ways to deliver
these via robust biotechnological processes. The
various approaches that have been followed to do so
are discussed in this contribution that is also
addressing the concept of the minimal microbiome as
well as the production of the synthetic communities
that can be instrumental in new therapeutic avenues
to modify the intestinal microbiota.
Our intestinal tract is colonized since birth by complex
communities of microbes that show specific spatio-
temporal organizations, differ in composition between
individuals, and contribute to health and disease
(Zoetendal et al., 2006). Considerable progress has been
made in recent years to describe the structure and func-
tion of the intestinal microbiota that belong to the major
phyla of the Firmicutes, Actinobacteria, Bacteroidetes,
Proteobacteria and Verrucomicrobia (Rajilic´-Stojanovic´
et al., 2007). However, the majority of the over 1000
species-like groups of the human intestine have not yet
been cultured (Zoetendal et al., 2008). Facilitated by the
advances in sequencing technologies, significant atten-
tion has been given to culture-independent and high-
throughput approaches that generated important baseline
information on the intestinal microbiota composition, the
description of a reference metagenome of 3.3 Mb, and its
structuring into clusters, termed enterotypes (Qin and
the MetaHit Consortium, 2010; Arumugam and the
MetaHit Consortium, 2011; Huttenhower and the Human
Microbiome Project Consortium, 2012).
The application of the high-throughput technologies
confirmed earlier observations that adults have a unique
and stable microbiota (Zoetendal et al., 1998). This has
been recently extended by the highly accurate, reproduc-
ible and deep analysis of the microbiota of thousands of
adults that revealed all of them to have a different com-
position (J. Salojarvi and W. M. de Vos, unpublished
observations using the HITChip, a phylogenetic microar-
ray) (Rajilic´-Stojanovic´ et al., 2009). As the systematic
analysis of the human microbiota is only recently emerg-
ing at this large scale, there are not many studies that
addressed the long-term dynamics of the intestinal micro-
biota. A deeply sampled longitudinal study of two subjects
for over a year showed the microbial composition in faecal
samples to be rather stable in contrast to that in other
body parts, such as skin and oral cavity (Caporaso et al.,
2011). Similarly, considerable stability of the of the faecal
communities was observed in healthy subjects that were
followed for over 10 years and maintained their charac-
teristic personal microbiome (Rajilic´-Stojanovic´ et al.,
2012). Other longitudinal studies indicated that the micro-
biota composition is affected by diet, antibiotic use and
intestinal transit but possibly also by less well-studied
lifestyle factors, such as time zone travelling (Flint et al.,
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2012; Jalanka-Tuovinen et al., 2011). An inherent deter-
minant of this dynamics could be formed by bacteri-
ophages that are detected in faecal samples and
metagenomes (Qin and the MetaHit Consortium, 2010;
Minot et al., 2011; Reyes et al., 2012). As typical oscilla-
tions have not been observed, it is not yet clear how
bacteriophages control the intestinal microbiota but in
analogy with other systems, it may be speculated that the
intestinal microbiota is in the carrier state with virulent
bacteriophages contributing to its stability (de Vos, 1989).
The abundance of accurate approaches to monitor the
composition and coding capacity of the intestinal micro-
biota also greatly advanced the analysis of the differences
in intestinal microbiota composition of healthy and dis-
eased subjects. Presently, correlations between specific
intestinal microbes or microbial patterns have been deter-
mined for several dozens of diseases, varying from
severe intestinal inflammations to cancer and obesity, as
reviewed recently (de Vos and de Vos, 2012). However,
causal relations are scarce and hard to establish, as there
are many microbiological, medical and ethical issues to
deal with. An exception is the use of faecal transplanta-
tions of the intestinal microbiota that is receiving increas-
ing popularity in human interventions since this practice
not only provides causal relations but also shows consid-
erable efficacy in treating various diseases, supporting
the importance of the intestinal microbiota. Remarkably,
there is a large discrepancy between the low-key technol-
ogy used in this treatment and the sophisticated knowl-
edge of the intestinal microbiome. Hence, this caveat is
addressed here with specific attention for next-generation
therapies at the interface of medical practice and micro-
bial biotechnology.
Development of faecal transplantation: from human
to animals and back
Long before the discovery of microbes, the concept of
transplanting faecal material has been practiced, support-
ing the often-empirical nature of the medical practice.
Records in Chinese medicine documenting the transfer of
faecal suspensions date for over 1000 years, as reviewed
recently (Zhang et al., 2012). This include the first descrip-
tion by Ge Hong, a medical doctor during the Djong-ji
dynasty (fourth century), who could cure patients suffering
from food poisoning or severe diarrhoea by making them
consume faecal suspensions from healthy donors. Simi-
larly, during the Ming dynasty (16th century) Li Shizen
provided detailed descriptions of faecal therapies for the
effective treatment of certain abdominal diseases, as
noted recently (Zhang et al., 2012). Remarkably, the
concept of transferring intestinal samples in veterinary
practice was in use around the same time in Europe
where the Italian anatomist Fabricius Aquapendente (17th
century) described the practice of inoculating rumen fluid
presumably into cows that had lost the capacity to rumi-
nate (Borody et al., 2004). This procedure is still practiced
today when cud, which is the material that is brought up
into the mouth by a cow from its first stomach to be
chewed again, is used to inoculate young calves via the
oral cavity (Pounden and Hibbs, 1950). In a more extreme
situation, this inoculation takes place in adult cows with
rumen fluid directly obtained via a fistula from a well-
producing cow. This process, also known as transfauna-
tion since both microbes and protozoa are transferred, is
an effective therapy in acidosis of cows fed high grain
levels that is caused by overgrowth of mainly Streptococ-
cus bovis (Klieve et al., 2003). In the second part of
last century, the practice of faecal transplantation was
extended to avian species in the so-called Nurmi concept
where newly hatched chicks are inoculated by mixtures of
chicken faeces (Nurmi and Rantala, 1973). This effec-
tively increased the colonization resistance and protected
the chicken from infections, notably from Salmonella spp.
Presently, this practice is still in place and freeze-dried
preparations of faecal microbiota from pathogen-free
chicken are manufactured and commercialized (Stavric,
1992; Nakamura et al., 2002; Revolledo et al., 2009).
Some 50 years ago, human faecal transplantations
were again documented in the medical practice by the
work of Dr Ben Eiseman (Eiseman et al., 1958). Four
enterocolitis patients were treated with faecal enemas
(delivery via the colon) and a rapid recovery of all of them
was observed. With the knowledge of the present time,
these patients probably would have been described as
suffering from Clostridium difficile infection (CDI). Follow-
ing this report dozens of reports have appeared showing
the success of faecal transplantation in recurrent or
chronic CDI and these include over 500 cases as
reviewed recently (Gough et al., 2011; Borody et al.,
2012). The various avenues used for these and other
transplantations, their success in the medical practice and
the options for applying microbial biotechnology are dis-
cussed below.
Faecal transplantation practice
Transplanting faecal microbiota in its simplest form is the
consumption of intestinal microbiota. This is a natural
process as it is likely to occur in early life when we are
born virtually sterile and are colonized rapidly by specific
microbial communities that are only found in the human
intestine. So we all start our life with at least one, but most
likely multiple, faecal transplantations. This is not an issue
to be discussed at the first baby visit, dinner table or
before breakfast, as was recently noted (Economist,
2012). Hence, there are a great variety of euphemistic
descriptions of the material used, including yellow soup,
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liquid gold or just Julia Flora, termed after the co-worker
who donated the original culture (Schoorel et al., 1980; P.
Heidt, pers. comm.). Similarly, the practice itself enjoys
over a dozen of terms, the most recent one being
‘repoopulate’ (Petrof et al., 2013). The way the treatment
is performed varies considerably and ranges from top to
bottom, including simple oral consumption, small intesti-
nal infusion via a nasogastric or naso-duodenal tube,
transfer via esophago-gastroduodenoscopy or colonos-
copy, or delivery by a colonic retention enema that even
can be applied at home. In many cases, the microbial
load of the intestinal tract is reduced by a bowel lavage
or consumption of laxatives. The delivery mode also
explains the wording used for the practice that may vary
from faecal duodenal infusion to colonic bowel transplan-
tation. Moreover, often terms as bacteriotherapy or faecal
microbiota transplantation are used. However, these do
not correctly describe the followed procedure, as the
faecal material that is transferred contains more than only
microbes as is described below (see also Fig. 1)
Characterization of faecal material
for transplantation
In contrast to the great interest in the microbial make-up,
there are only a few data on the abiotic composition of
faecal material. In a thorough study of adults consuming
a typical British diet (385 g of carbohydrates, 85 g of
protein, 108 g of fat and 22 g of dietary fibre) it was found
that on average the faecal discharge was close to 100 g
per day and consisted for 75% of water. However, when
the dry matter was considered, approximately half (55%)
consisted of microorganisms, while the remaining part
included fibres such as cellulose, as well as soluble mate-
rial (24%) (Fig. 1A) (Stephen and Cummins, 1980). The
latter also included polymers such as mucus, proteins and
fat and expectedly all sorts of small soluble molecules
including bile acids that constitute a sink for cholesterol
degradation products such as catechol, indols and
sulfides that generate the familiar odours, and the char-
acteristic short-chain fatty acids that are produced at a
level of up to 100 mM in average faecal samples (Flint
et al., 2012). In most faecal transplantations no efforts are
made to purify or enrich the microbial fractions and hence
the therapeutic preparations contain all or most of these
compounds.
Some pre-treatments are done with the faecal samples
that are administrated via the upper intestinal tract and
include diluting, blending and filtering the faecal micro-
biota (Vrieze et al., 2012). Protective measures are taken
to reduce the exposure to oxygen-rich situations but
cannot be prevented. Analysis of the microbiota before or
after this treatment did not show major differences (E. G.
Zoetendal and W. M. de Vos unpubl. obs.). However, the
viability of the preparations has not been tested. This also
has not been done for the frozen faecal samples that are
used for colonic delivery in CDI patients and also included
washing and subsequently storage in cryoprotectants,
such as glycerol (Hamilton et al., 2012). This is all of
relevance, since it has been reported that the majority of
faecal microbes are dead or damaged (Fig. 1B). This is
not a surprise as the end-of-the-pipeline fermentations
that take place in the colon are not there to preserve
viability. The solids contain many toxic components, the
most relevant is bile that has powerful antimicrobial prop-
erties (Begley et al., 2005). The viability of faecal micro-
biota has been determined in Dutch subjects consuming a
regular diet using advanced flow cytometry with functional
fluorescent probes (Ben-Amor et al., 2002). It was
observed that about half of the microbes (49%) are dead,
one-third are alive (32%), and a smaller fraction is
damaged and most likely only can be cultured with
specific treatments as described previously (Fig. 1B)
(Ben-Amor et al., 2002). This is not likely to happen during
the present treatments of faecal transplantation that often
require manipulations under less strict anaerobic and pro-
tecting conditions than the ones used to preserve viability
(Ben-Amor et al., 2002).
In conclusion, it is fair to assume that the vast majority
of the transplanted microbes are dead. It cannot be
excluded that these, together with other abiotic com-
pounds present in the faecal samples (Fig. 1A), play a
role in the success of the faecal transplantations and this
is an area that needs further study. Importantly, the viable
microbiota that can be recovered from faecal samples
shows a non-uniform distribution with less than expected
Bacteroidetes, some major Clostridium groups and Bifi-
dobacterium spp. (Ben-Amor et al., 2002). Remarkably,
butyrate-producing bacteria such as Eubacterium hallii
were found to be present in the viable fraction. This is of
interest as we recently found that E. hallii, which converts
lactate and acetate into butyrate, was enriched in
the ileal microbiota of metabolic syndrome subjects
that were cured from their insulin-resistance by faecal
Viable Dead DamagedMicrobes Fibers Solubles
Fig. 1. Faecal composition. The distribution of dry weight constitu-
ents (left; solubles represent the soluble material) (Stephen and
Cummins, 1980) and the differentiation of the microbiota into
viable, dead and damaged cells (Ben-Amor et al., 2005).
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transplantation (Vrieze et al., 2012). These differential
effects on viability may constitute an important lead for
further work that aims to provide cause–effect relations
between the transplanted microbiota and the health
outcomes.
Present success of faecal transplantation
Following the success of faecal transplantations in the
treatment of colitis and recurrent CDI patients in the last 50
years, a variety of other diseases have been targeted. An
important one was the first case report in 1989 by Dr Justin
D Bennet of Ulcerative Colitis (UC), a severe colitis of the
colon (Bennet and Brinkman, 1989). He suffered himself
from UC and after describing many unsuccessful treat-
ments he was finally cured by repeated colonic application
of large amounts of faecal material from a healthy donor.
Since then, many applications in CDI, UC and others have
been pioneered, mostly as case studies (Borody and
Khoruts, 2011). Presently, successful faecal transplanta-
tions have been described for approximately half a dozen
of diseases, some of which with large numbers of treated
patients (Table 1). There seems not to be a great difference
in the success rate when using oral, duodenal and colonic
delivery as is evident from the treatment of recurrent CDI.
However, in all cases specific precautions are taken in the
selection of the donor, varying in stringency from general
health to large lists of criteria that have to be met, such as
absence of HIV and other viruses, intestinal complaints, or
unsafe sex or use of illicit drugs (Vrieze et al., 2013). Apart
from CDI and UC, these include irritable bowel syndrome
(IBS) that is also characterized by an aberrant microbial
composition (Rajilic´-Stojanovic´ et al., 2011). In addition,
indications exist for the successful treatment of chronic
fatigue syndrome (Borody et al., 2012) and multiple scle-
rosis (Borody et al., 2011) but these are only based on
single studies, as has been reviewed recently (Vrieze
et al., 2013). An increasing number of studies is also
addressing the microbiota composition and function in the
donor and the recipient before and after transplantation
(Table 2). This is an important addition to the learning curve
and should be standard practice for new interventions as it
will contribute to further developing faecal transplanta-
tions. Some of the most relevant findings are summarized
below.
In the over 500 cases where faecal transplantations
have been practiced on recurrent or chronic CDI patients,
an average disease resolution of over 95% has been
reported (Borody and Campbell, 2012). However, this
number may suffer from a publication bias as many
studies are small or represent successful case reports.
Several recent studies have approached faecal transplan-
tation in CDI in a systematic way with many patients. In a
study at Helsinki University, a total of 70 recurrent CDI
patients were treated by colonic delivery, resulting in 66
cured patients (94%) (Mattila et al., 2012). In another
study in the Amsterdam Medical Centre, a three-arm
study was set up where 42 recurrent CDI patients either
received vancomycin, vancomycin and a bowel lavage, or
all these treatments followed by duodenal infusion of
healthy donor faeces (van Nood et al., 2013). After an
interim evaluation, the study was stopped by the medical–
Table 1. Diseases treated by faecal transplantation.
Disease N Delivery Reference
C. difficile infection 70 C Mattila et al. (2012)
C. difficile infection 16 D van Nood et al. (2013)
Insulin resistance (MetS) 9 D Vrieze et al. (2012)
Ulcerative colitis 6 C Borody et al. (2003)
Irritable bowel syndrome 30 C Andrews et al. (1995)
Chronic fatigue syndrome 60 C Borody et al. (2012)
Multiple sclerosis 4 C Borody et al. (2011)
Metabolic acidosis 1 O Schoorel et al. (1980)
Recolonization after AD 6 O van der Waaij et al. (1977);
Heidt et al. (1983)
The number (N) of described cases is indicated as are the different
modes of delivery (D, duodenal; C, colonic or caecal; O, Oral).
Studies with the largest number of patients reported are listed. AD,
antibiotic decontamination.
Table 2. Lessons learned from transplantations.
Patient Number Major change Reference
CDI 1 Increased diversity Khoruts et al. (2010)
Increase in Bacteroidetes
CDI 6 Increased diversity – not all successful Shahinas et al. (2012)
Increase in Bacteroidetes 0026; Firmicutes
Decrease in Proteobacteria
CDI 3 Increased diversity – like donor in 2/3 Hamilton et al. (2013)
Increase in Bacteroidetes 0026; Firmicutes
Decrease in Proteobacteria 0026; Actinobacteria
CDI 9 Increased diversity – like donors in 9/9 van Nood et al. (2013)
Increase in Bacteroides, some Firmicutes
Decrease in Proteobacteria
MetS 8 Slightly increased diversity Vrieze et al. (2012)
Increase in some butyrate producers
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ethical board since the transplanted patients showed
much better recovery than those receiving either of the
other treatments – in total 13 of the 16 CDI patients
recovered immediately after the faecal transplantation
and two of the remaining three after a second infusion.
This contrasts markedly with the other treatments that
cured either four or three out of 13 with vancomycin, or
vancomycin and bowel lavage respectively. Interestingly,
the several of these that did not respond to the
vancomycin-based treatments received an off-protocol
faecal transplantation and 15 of them recovered immedi-
ately. Altogether, this resulted in a successful treatment of
30 of the 33 CDI patients (91%). In the latter study the
microbiota was studied extensively (van Nood et al.,
2013; S. Fuentes and W. M. de Vos, unpubl. obs.). The
recurrent CDI patients were all characterized by a con-
sistent and reproducible very low intestinal microbiota
diversity that was immediately corrected to donor levels
after the faecal transplantation and this stable and healthy
situation was followed up for 6 weeks in multiple patients.
This analysis extended previous studies in a single
(Khoruts et al., 2010) or limited number of subjects with
fresh (Shahinas et al., 2012) or frozen faeces (Hamilton
et al., 2012) (Table 2). A dramatic increase in Bacter-
oidetes, some Firmicutes, including butyrate-producing
ones, as well as a reduction in pathobionts belonging to
the Proteobacteria were observed (van Nood et al.,
2013). This all indicated a drastic conversion from a low
diversity but highly inflammatory microbiome into that with
the characteristics of a healthy microbiota (De Vos and De
Vos, 2012). While some individual differences can be
observed, the global picture is the same in this and other
reported analyses of the microbiota after CDI transplan-
tations (Table 2). This indicates that the nature of the
microbiota (fresh or frozen), the delivery mode (duodenal
or colonic), or the location, origin or dietary habits of the
donors, do not affect the final outcome. It also confirms
the earlier observations that the intestinal ecosystem in
the CDI patients is so disturbed that the donor microbes
rapidly start occupying the available niches resulting in a
normally functioning intestinal microbiota (Khoruts et al.,
2010).
Most faecal transplantations are performed with stool
samples from multiple healthy donors, often family
members. Occasionally, transplantations are performed
with one or a preferred donor. However, in a recent study
a total of 32 recurrent CDI patients were treated with an
enema of a mixture of intestinal microbes derived from a
single healthy middle-aged donor in 1994, which had
been re-cultivated under strict anaerobic conditions for
over 10 years (Jorup-Rönström et al., 2012). A simple
peptone-yeast medium was used for this subculturing that
included egg yolk as a source of cholesterol. Usually such
culturing steps decrease the microbial diversity rapidly but
the effectiveness of this yet undefined mixture appeared
to persist, as 22 out of the 32 patients (69%) could be
cured. Remarkably, the mixture was administered as a
30 ml suspension by a 50 cm rectal catheter without prior
laxation, although precautions were taken to keep the
enema as long as possible. This contrasts with other
administration procedures that use usually over 100 g of
faecal material that is inserted after bowel lavage. This,
the unusual way of delivery, and the nature of the inocu-
lum may be among the factors explaining the lower than
elsewhere reported curing rates.
The vast majority of the described studies do not have a
control group, most likely as it is not ethical to withheld the
best treatment from the patients as the experience with the
CDI transplantation indicates (van Nood et al., 2013).
Moreover, the selection of a control treatment is far from
simple and specifically not in the case of transplantations.
However, an elegant solution has been provided in a large
study with patients suffering from metabolic syndrome
(MetS; Vrieze et al., 2012). Here a control group of nine
subjects did not receive faecal transplants from lean
donors as the treatment group, but were transplanted with
their own faecal samples in a so-called autologous trans-
plantation. Only the treatment group receiving the lean
donor transplants showed loss of MetS as evidenced by an
increased insulin sensitivity (Table 1). As this study was
performed in a blinded way, it represents the first double
blind, placebo-controlled faecal transplantation study,
adding both credibility and power to the observed results.
Moreover, a deep microbiota analysis was also performed
in this study and showed less pronounced differences than
that after transplantation of the recurrent CDI patients.
However, small but reproducible differences could be
detected in the cured treatment group, which were absent
in the autologous group that received their own microbiota
(Vrieze et al., 2013). These included an increase of
butyrate-producing bacteria (Roseburia intestinalis in the
lower and E. hallii in the upper intestinal tract) that was
accompanied by a reduced number of Proteobacteria,
including Escherichia coli (Table 2). This suggests a similar
situation, though not so prominent, as observed after the
treatment of recurrent CDI patients, viz. a reduction of
potential inflammatory Gram-negative bacteria by those
that are capable of producing butyrate after faecal trans-
plantation with a healthy donor.
An unusual study that has received only little attention
involves the so-called Julia Flora. This term relates to the
faecal microbiota from a healthy donor that was main-
tained in germ-free mice and could be easily delivered via
the oral route (Van der Waaij et al., 1977). This Julia Flora
was used to rescue a 3-year-old boy with short bowel
syndrome who suffered from metabolic acidosis due to
overproduction of D-lactic acid (Schoorel et al., 1980). As
described above, acidosis is often encountered in cattle
Fame and future of faecal transplantations 320
© 2013 The Author. Microbial Biotechnology published by John Wiley & Sons Ltd and Society for Applied Microbiology, Microbial
Biotechnology, 6, 316–325
due to S. bovis overgrowth (Klieve et al., 2003). Here this
could be caused by similar mechanism as a higher than
normal level of Gram-positive bacteria was observed in
the boy’s stool. Daily oral administration of the Julia Flora
for 5 consecutive days was sufficient to cure the boy and
he did not observe any negative effects 9 months after
discharge from the hospital (Schoorel et al., 1980).
In conclusion, the successes of faecal transplantation
range from various levels of colonic inflammation to meta-
bolic diseases. This extends the association of these dis-
eases with the intestinal microbiota by providing a clear
causal relation with the faecal components (De Vos and
De Vos, 2012). The microbiota analysis confirms and
extends this, while providing global insight in how the
various taxonomic and functional groups of the recipient
are replaced by that of the donor. Moreover, detailed
analysis of the microbial changes over time will allow the
association of specific bacteria with health status, such as
the butyrate-producing E. hallii in the case of MetS
(Table 2). This type of approaches together with further
metagenomic, functional and network analyses will
provide a wealth of data that may deliver new leads for
defining the minimal microbiome and constructing syn-
thetic microbial communities. This is supported by suc-
cesses with undefined microbial mixtures, maintained in
germ-free mice or subculturing in the laboratory, in curing
metabolic acidosis or treating recurrent CDI patients
(Schoorel et al., 1980; Jorup-Rönström et al., 2012).
Further steps towards the development of synthetic com-
munities are discussed below.
Towards synthetic communities
Long before the present interest in our intestinal microbi-
ome and bringing faecal transplantations to the next level,
various attempts have been reported on the development
of synthetic communities. These are presented here
together with the most recently developed mixtures
(Table 3).
An unusual set of transplantations that followed inten-
sive treatments with antibiotics to decontaminate the
intestinal tract, have described as early as 1973. At this
time, isolators were developed to protect patients with
immunological deficiencies, such as those treated with
acute leukaemia. Some of these studies are detailed
here, since it seems that these have escaped the atten-
tion of those active in the field of faecal transplantations.
In an extensive report describing a complete contain-
ment system, it was reported that immune-compromised
children and adults could enter a germ-free state after
long-term antibiotic treatments (Dietrich and Fliedner,
1973). After the appropriate therapy and cure of the
disease in these patients, they had to be colonized in
order to enter the ordinary environment. This was per-
formed by a cascade of oral inoculations of single bac-
terial strains (Bifidobacteria, Lactobacilli, E. coli and
Enterococci), followed by a rectal insertion of a faecal
sample from a healthy subject. It was found that each
bacterium colonized immediately without symptoms of
disease in two of such germ-free children. A single case
was described in more detail and included a gnotobiotic
child that had been on oral treatment of 500 mg day-1 of
gentamicin, which was probably contaminated by two
aerobic spore-forming bacilli that subsequently colo-
nized. This child received first 106 and subsequently
1010 cells of different strains of Bifidobacteria, delivered
with a milk diet. These inoculated strains grew out to up
to approximately 108–1010 bifidobacterial cells per
gram faecal material, outcompeting the spore for-
mers by a factor of 10–1000. After 4 months the faecal
Table 3. Undefined cultures and defined consortia used in microbiota transplantations.
Host Number Composition Reference
Germ-free children 2 Two Bifidobacterium strains, two spore formers (most likely contaminants
of an antibiotic)
Dietrich and Fliedner (1973)
C-section babies 6 Human donor microbiota maintained in germ-free mice Raibaud et al. (1975)
AD patients 5 Human donor microbiota maintained in germ-free mice van der Waaij et al. (1977); Heidt
et al. (1983)
CDI patients 32 Human donor microbiota subcultured for 10 years Jorup-Rönström et al. (2012)
CDI mice 20 S. warneri, E. hirae, L. reuteri, Anaerostipes sp. nov., Bacteroidetes sp.
nov., Enterorhabdus sp. nov.
Lawley et al. (2012)
CDI patients 6 E. faecalis, C. innocuum, C. ramosum, B. ovatus, B. vulgatus,
B. thetaiotamicron, E. coli (2), C. bifermentus, P. productus
Tvede and Rask-Madsen (1989)
CDI patients 2 A. intestinalis, B. ovatus, Bif. adolescentis (2), Bif. longum (2), Bl.
producta, C. cocleatum, Col. aerofaciens, D. longicatena (2), E. coli,
Eub. desmolans, Eub. eligens, Eub. limosum, Eub. rectale (4), Eub.
ventriosum, F. prausnitzii, Lach. pectinoshiza, L. paracasei, L. casei,
Par. distasonis, Raoultella sp., R. faecalis, R. intestinalis, Rum. torques
(2), Rum. obeum (2), S. mitis
Petrof et al. (2013)
AD, antibiotic decontamination. E., Enterococcus; C., Clostridium; B., Bacteroides; E., Escherichia; P., Propionibacterium; A., Anaerostipes;
Bif., Bifidobacterium; Col., Colinsella; Eub., Eubacterium; F. Faecalibacterium; Lach., Lachnospira; Par., Parabacteroides; R., Roseburia;
Rum., Ruminococcus; S., Streptococcus; L., Lactobacillus. The species indicated in bold are the main constituents of the mixtures.
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transplantation was performed and the child left the iso-
lator (Dietrich and Fliedner, 1973).
Around the same time, faecal transplantations were
used to conventionalize caesarean-section (C-section)
delivered children, suspected of congenital combined
immunodeficiency (Raibaud et al., 1975). Ten days after
their delivery, these were fed a suspension of intestinal
content of germ-free mice that had been colonized by a
diluted human faecal sample. This is the first description
of the oral transplantation by a humanized microbiota
derived from mice. A similar approach was followed a few
years later when a humanized and non-pathogenic micro-
biota was obtained from a healthy donor, named J.F. (Van
der Waaij et al., 1977). The generated microbiota was
termed first J.F. flora, and later named Julia Flora (see
above and Table 2) and also Human Donor Flora (HDF).
Remarkably, during the maintenance in mice, E. coli was
lost as a major component of the microbiota and mainly
consisted of anaerobic bacteria (Heidt et al., 1983). We
now know from various studies that the human microbiota
in germ-free animals may change rapidly in structure and
function (El Aidy et al., 2012). This J.F. flora was used as
an oral inoculum to repeatedly (up to five times) recolo-
nize a series of five immunocompromised and hence
isolator-kept patients that had been receiving antibiotics in
a treatment known as antibiotic decontamination (AD).
While virtually sterile before transplantation, the colonic
counts rapidly increased after the colonization. However,
it was noted that the colonization resistance of the trans-
planted patients was not as good as that of a normal
healthy subject (Van der Waaij et al., 1977). Whether this
is due to the composition of the Julia Flora or the impact
of the compromised hosts cannot be said but it appeared
that the quality of the J.F. flora (then termed Julia Flora)
was sufficiently high to cure metabolic acidosis in a young
boy (Schoorel et al., 1980; see above).
A series of early but very important experiments with
synthetic communities were reported around the same
time by Tvede and Rask-Madsen (1989). From 20 intes-
tinal single strain isolates, they selected 10 strains,
several of which showed inhibitory activity against C. dif-
ficile isolated from the six patients with chronic CDI. These
patients were treated successfully with faecal samples
from healthy relatives or the strain mixture that were all
rectally installed. One patient was treated with a faecal
enema only, one with a faecal enemas that were unsuc-
cessful and subsequently with the strain mixture, and the
remaining four only with the strain mixture that was rec-
tally installed (Table 3). Faecal samples of the patients
before these treatments did not contain detectable Bacter-
oides spp. in line with later observations described above
(Table 2). This is the first description of a synthetic mixture
of intestinal bacteria that shows success in curing five CDI
patients from their recurrent CDI. It also showed that the
developed mixture was superior to faecal transplantation
in the one case tested. The mixture consisted of three
Bacteroides spp. that all were inhibited by the patients’
C. difficile. However, one E. coli strain as well as the
Clostridium bifermentans and Peptostreptococcus pro-
ductus strains showed antagonistic activity against C. dif-
ficile. In this context it is relevant to note that recently a
two-component modified antimicrobial peptide, thuricin
CD, was detected in an intestinal Bacillus thuringiensis,
which showed strong inhibitory activity against C. difficile
in vitro and in a distal colon model (Rea et al., 2010;
2011). A long-term follow-up of the patients treated with
the synthetic mixture was described and included analysis
of the faecal samples by anaerobic culturing (Tvede and
Rask-Madsen, 1989). It was observed that mainly the
Bacteroides spp. colonized and it was suggested that
colonization by these bacteria may provide a natural
defence against C. difficile although synergistics effect of
the inhibiting species could not be excluded. These hall-
mark findings attracted quite some attention but also were
criticized as is usually the case when novel approaches
are reported. The suggestions that oral therapies with
probiotic bacteria or yeasts could be a better approach
were adequately rebutted (Seal et al., 1989; Tvede and
Rask-Madsen, 1990). The question whether 10 strains
are too many or too few has not yet been answered, even
not with the molecular approaches available now.
As may be expected from the abundance of the recur-
rent of chronic CDI, most recent studies in developing
synthetic communities have been focusing on this
disease. An elegant mouse study was recently reported
and included a CDI model that was tested with the best
synthetic communities selected via some combinatorial
approach. Best results were obtained with a mixture of six
species that included some new mouse isolates (Lawley
et al., 2012). How the mouse isolates will perform in the
human intestinal tract is not known. Similarly, it remains to
be seen what regulatory hurdles have to be overcome
before human trials can be done with this mixture of
mouse strains. However, this study clearly demonstrates
the success of an avenue that can be followed to develop,
maintain and test synthetic communities for treating CDI
patients. This extends the other recent study where a
human intestinal microbiota was maintained for over 10
years in the laboratory (Jorup-Rönström et al., 2012; see
above). A recent human pilot study re-addressed the
issue of using synthetic microbial communities for curing
CDI (Petrof et al., 2013). A total of 33 strains of a variety
of bacterial groups were isolated from the stool of a
healthy donor, combined and cultured, and subsequently
used to treat two patients with recurrent CDI who had
failed to respond to antibiotic treatments (Table 3). Follow-
ing delivery by colonoscopy, it was found that the patients
were cured while analysis of the resulting intestinal micro-
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biota indicated establishment of some of the new strains.
This proof-of-principle study confirms the earlier results of
Tvede and Rask-Madsen (1989).
Future of faecal transplantations
Experimental observations ranging from traditional
Chinese medicine to those of modern evidence-based
medicine, have provided clear evidence that faecal trans-
plantation may work in a series of diseases, recurrent or
chronic CDI being the best investigated one (Kelly, 2013;
van Nood et al., 2013). The early results initiated in the
late seventies and early eighties of large century, with
undefined mixtures as well as defined consortia as pio-
neered by Tvede and Rask-Madsen (1989), indicate
strongly that synthetic communities are a feasible
approach. This is confirmed by the recent but still anec-
dotal studies in mice and man (Table 3). There is a clear
need to further develop the concept of synthetic microbial
communities to treat CDI and possibly other diseases.
The question on how many strains or species are
needed, raised over a dozen years ago is still actual.
This brings forward the concept of the minimal microbi-
ome that can be defined as the smallest set of microbes
and/or microbial functions needed to develop a stable
community. Large data sets of microbial communities,
their metagenomes and function are being collected
worldwide. These can be mined for the networks of
microbes and their functions that may provide leads on
how such minimal microbiome would look like. Similarly,
the analysis of the interactions between intestinal
microbes and the host are being studied at a systems
level (Martins dos Santos et al., 2010). This will allow the
identification of microbial components that can be used
to predict the minimal microbiomes. Moreover, there is a
great variety of new avenues have been developed that
can be followed to isolate and culture new microbial
strains, varying from germ-mice to functionalized solid
surfaces (Ingham et al., 2007; 2012; Goodman et al.,
2011). Hence, there are plentiful possibilities to develop
these minimal microbiomes into products based on syn-
thetic microbial communities.
The advantages of synthetic microbial communities are
clear as the composition of the synthetic mixtures can be
controlled, tested extensively for the absence of unde-
sired pathogens and viruses, and can be reproducibly
manufactured. Moreover, the viability can be controlled
and optimized. A large number of industrial fermentations
rely on this principle and include the aseptic production of
freeze-dried or frozen combinations of viable strains such
as in the production of multiple strain starter cultures or
probiotics (de Vos, 2011). Implementation of these syn-
thetic microbial communities in next-generation therapies
would greatly benefit the patients, further advance our
understanding of the intestinal microbiome, and intensify
the relation between medical practice and microbial
biotechnology.
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